SOBI:STO
Swedish Orphan Biovitrum
437,40 SEK
0,00%
(0,00) 1 d.
14. 10., 17:29:59 GMT+2 · SEK
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre SOBI…
Trh. kap.
156,43 mld.
Priem. obj.
255,84 tis.
Objem
0,00
Pomer cena/zárobky
116,82
Max. za 52 týž.
487,00 SEK
Min. za 52 týž.
293,60 SEK
Výnosy na akciu
3,74 SEK
Akcie v obehu
357,64 mil.
Počet zamestnancov
2 tis.
Trh. kap.
156,43 mld.
Priem. obj.
255,84 tis.
Objem
0,00
Pomer cena/zárobky
116,82
Max. za 52 týž.
487,00 SEK
Min. za 52 týž.
293,60 SEK
Výnosy na akciu
3,74 SEK
Akcie v obehu
357,64 mil.
Počet zamestnancov
2 tis.
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
Benzinga
·
pred 19 minútami
Stock Market: Will S&P 500 Open Up or Down Today?
MarketBeat
·
pred 54 minútami
Nasdaq (NDAQ) Projected to Release Quarterly Earnings on Thursday
Foreign Policy Journal
·
pred 1 hodinou
U.S. Markets Close Lower As Tech Selloff Drags Down Dow Jones Industrial Average (DJIA), S&P 500
Profil
Sobi - Swedish Orphan Biovitrum AB is an international biopharmaceutical company focused on rare diseases. The company develops, commercializes, and delivers therapies in the fields of haematology, immunology and specialty care. Headquartered in Stockholm, Sweden, with major hubs in Basel, Switzerland, and Waltham, USA.
Sobi has a global presence in approximately 30 countries and provides medicines to patients in many more around world. The company develops treatments for patients living with complex and chronic rare conditions and maintains a pipeline of development and lifecycle management programs focused on advancing innovative therapies for diseases with significant unmet medical needs. Wikipedia
Informácie o subjekte Swedish Orphan Biovitrum
Generálny riaditeľGuido Oelkers
Zamestnanci2,12 tis.
Dátum založenia1939
Hlavné sídlo-
Odvetvie-
Websobi.com